NASDAQ:RCKT Rocket Pharmaceuticals (RCKT) Stock Price, News & Analysis → Elon Musk’s PRIME is Set to Shock the World (From InvestorPlace) (Ad) Free RCKT Stock Alerts $21.42 -0.30 (-1.38%) (As of 05/24/2024 ET) Add Compare Share Share Today's Range$21.41▼$22.0250-Day Range$21.42▼$27.8652-Week Range$14.89▼$32.53Volume584,227 shsAverage Volume589,497 shsMarket Capitalization$1.94 billionP/E RatioN/ADividend YieldN/APrice Target$52.13 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Rocket Pharmaceuticals alerts: Email Address Rocket Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside143.3% Upside$52.13 Price TargetShort InterestBearish10.84% of Shares Sold ShortDividend StrengthN/ASustainability-0.81Upright™ Environmental ScoreNews Sentiment0.27Based on 13 Articles This WeekInsider TradingSelling Shares$10.83 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.85) to ($1.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.69 out of 5 starsMedical Sector62nd out of 923 stocksPharmaceutical Preparations Industry24th out of 414 stocks 4.4 Analyst's Opinion Consensus RatingRocket Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRocket Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rocket Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.84% of the outstanding shares of Rocket Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRocket Pharmaceuticals has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Rocket Pharmaceuticals has recently decreased by 10.55%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRocket Pharmaceuticals does not currently pay a dividend.Dividend GrowthRocket Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRocket Pharmaceuticals has received a 74.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Rocket Pharmaceuticals is -0.81. Previous Next 1.8 News and Social Media Coverage News SentimentRocket Pharmaceuticals has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Rocket Pharmaceuticals this week, compared to 8 articles on an average week. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rocket Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,830,243.00 in company stock.Percentage Held by Insiders31.10% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.39% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rocket Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.85) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rocket Pharmaceuticals is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rocket Pharmaceuticals is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRocket Pharmaceuticals has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Rocket Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon Musk’s PRIME is Set to Shock the WorldMust-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing.Click here for the full story… About Rocket Pharmaceuticals Stock (NASDAQ:RCKT)Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Read More RCKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RCKT Stock News HeadlinesMay 21, 2024 | insidertrades.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Sells $24,470.80 in StockMay 25 at 5:39 PM | msn.comRocket Lab launches NASA cubesat to study heat lost from Earth's poles (video)May 23 at 6:35 PM | detroitnews.comRocket Mortgage agrees to $3.5 million settlement in overtime pay caseMay 23 at 1:35 PM | cbsnews.comPiping plover Sea Rocket spotted on Chicago beachMay 23 at 1:35 PM | cbsnews.comNearly-extinct piping plover, Sea Rocket, spotted on Chicago beachMay 21, 2024 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson Sells 1,048 SharesMay 21, 2024 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Insider John Militello Sells 1,079 SharesMay 21, 2024 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) CEO Gaurav Shah Sells 9,790 Shares of StockMay 18, 2024 | americanbankingnews.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 10, 2024 | businesswire.comRocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)May 8, 2024 | marketwatch.comLockheed Martin Gets $861.3M U.S. Army Rocket-System PactMay 8, 2024 | usnews.comIsrael Reopens Key Crossing for Aid to Enter Gaza That Was Closed Over Weekend Rocket AttackMay 8, 2024 | markets.businessinsider.comOptimistic Outlook for Rocket Pharmaceuticals with Advancing Pipeline and Solid FinancialsMay 7, 2024 | msn.comRocket Knight Adventures: Re-Sparked Collection - Official Pre-Order TrailerMay 6, 2024 | investorplace.comRCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024May 6, 2024 | msn.comRocket Pharmaceuticals GAAP EPS of -$0.66 beats by $0.01May 6, 2024 | msn.comRickie Fowler returning for 2024 Rocket Mortgage Classic in Detroit, tickets on sale nowMay 6, 2024 | businesswire.comRocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent ProgressMay 4, 2024 | msn.com3,000+ show up for Cleveland Cavaliers’ watch party at Rocket Mortgage FieldHouse (photos)May 2, 2024 | yahoo.comNASA selects Rocket Lab for back-to-back climate change research launchesMay 2, 2024 | msn.comRKT Stock Earnings: Rocket Companies Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | msn.comLouis Leterrier To Direct Sci-Fi Horror Pic ‘11817’; Rocket Science, CAA Launching Sales At CannesMay 1, 2024 | msn.comFortnite Update v29.40 Brings Star Wars to Battle Royale, Lego Fortnite, Fortnite Festival, and Rocket RacingApril 30, 2024 | sports.yahoo.comLions DE Aidan Hutchinson and his family talk Rocket Mortgage and reminisce the NFL DraftApril 30, 2024 | markets.businessinsider.comRocket Pharmaceuticals Upgraded to Buy: Here's WhySee More Headlines Receive RCKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today5/25/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RCKT CUSIPN/A CIK1281895 Webwww.rocketpharma.com Phone(609) 659-8001Fax646-224-9585Employees268Year Founded2018Price Target and Rating Average Stock Price Target$52.13 High Stock Price Target$65.00 Low Stock Price Target$39.00 Potential Upside/Downside+143.3%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,600,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.10% Return on Assets-46.90% Debt Debt-to-Equity Ratio0.04 Current Ratio10.47 Quick Ratio10.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book4.41Miscellaneous Outstanding Shares90,780,000Free Float62,549,000Market Cap$1.94 billion OptionableOptionable Beta1.12 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Kinnari Patel M.B.A. (Age 44)Pharm.D., Head of R&D, President & COO Comp: $849.93kMr. Mayo Pujols (Age 54)Chief Technical Officer Comp: $649.71kMr. Raj Prabhakar M.B.A. (Age 49)Chief Business Officer Comp: $619.13kMr. Aaron Ondrey (Age 47)Chief Financial Officer Mr. Martin Louis Wilson J.D. (Age 48)General Counsel, Chief Compliance Officer & Chief Corporate Officer Comp: $149.95kKevin GiordanoDirector of Corporate CommunicationsMs. Isabel Carmona J.D.Chief People OfficerMr. Jonathan Schwartz M.D. (Age 59)Chief Medical & Gene Therapy Officer Comp: $557.79kDr. Gayatri R. Rao J.D.M.D., Senior VP of Clinical Safety & Chief Regulatory OfficerMr. Carlos MartinChief Commercial Operations & Revenue OfficerMore ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSDicerna PharmaceuticalsNASDAQ:DRNAAurinia PharmaceuticalsNASDAQ:AUPHY-mAbs TherapeuticsNASDAQ:YMABHeron TherapeuticsNASDAQ:HRTXView All CompetitorsInsiders & InstitutionsComerica BankSold 23,500 shares on 5/17/2024Ownership: 0.589%Ikarian Capital LLCSold 92,630 shares on 5/17/2024Ownership: 0.327%Janus Henderson Group PLCBought 1,656,111 shares on 5/16/2024Ownership: 2.871%Gaurav ShahSold 9,790 sharesTotal: $228,596.50 ($23.35/share)Martin WilsonSold 1,048 sharesTotal: $24,470.80 ($23.35/share)View All Insider TransactionsView All Institutional Transactions RCKT Stock Analysis - Frequently Asked Questions Should I buy or sell Rocket Pharmaceuticals stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RCKT shares. View RCKT analyst ratings or view top-rated stocks. What is Rocket Pharmaceuticals' stock price target for 2024? 9 Wall Street research analysts have issued 1-year target prices for Rocket Pharmaceuticals' stock. Their RCKT share price targets range from $39.00 to $65.00. On average, they expect the company's share price to reach $52.13 in the next twelve months. This suggests a possible upside of 143.3% from the stock's current price. View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts. How have RCKT shares performed in 2024? Rocket Pharmaceuticals' stock was trading at $29.97 at the start of the year. Since then, RCKT stock has decreased by 28.5% and is now trading at $21.42. View the best growth stocks for 2024 here. When is Rocket Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our RCKT earnings forecast. How were Rocket Pharmaceuticals' earnings last quarter? Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) released its earnings results on Monday, May, 6th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($0.67) by $0.01. During the same period in the prior year, the firm earned ($0.73) earnings per share. What ETFs hold Rocket Pharmaceuticals' stock? ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Tema Cardiovascular and Metabolics ETF (HRTS), Harbor Health Care ETF (MEDI), Franklin Genomic Advancements ETF (HELX) and Harbor Disruptive Innovation ETF (INNO).Putnam BioRevolution ETF (SYNB) and What other stocks do shareholders of Rocket Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA). Who are Rocket Pharmaceuticals' major shareholders? Rocket Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.92%), Westfield Capital Management Co. LP (4.39%), Price T Rowe Associates Inc. MD (3.24%), Janus Henderson Group PLC (2.87%), Bamco Inc. NY (1.09%) and Russell Investments Group Ltd. (0.74%). Insiders that own company stock include David P Southwell, Gaurav Shah, Gotham Makker, John Militello, Jonathan David Schwartz, Kinnari Patel, Mark Andrew White, Martin Wilson and Rtw Investments, Lp. View institutional ownership trends. How do I buy shares of Rocket Pharmaceuticals? Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RCKT) was last updated on 5/26/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s PRIME is Set to Shock the WorldInvestorPlaceShocking $16T Elon Musk Crypto LeakCrypto 101 MediaJust $9 for a Year of Winning Market InsightsBehind the MarketsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsNew Options need New Trading StrategiesNetpicks$1,500 to $9,400 in one month? (A.I. Trade List)Prosper Trading AcademyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe Presidential candidate you should REALLY be worried aboutStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
